NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free TVTX Stock Alerts $6.06 -0.63 (-9.42%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$6.03▼$6.7750-Day Range$5.26▼$8.1552-Week Range$5.12▼$19.54Volume1.32 million shsAverage Volume1.34 million shsMarket Capitalization$461.35 millionP/E RatioN/ADividend YieldN/APrice Target$16.69 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Travere Therapeutics alerts: Email Address Travere Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.64 Rating ScoreUpside/Downside175.5% Upside$16.69 Price TargetShort InterestBearish16.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 5 Articles This WeekInsider TradingSelling Shares$364 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.66) to ($1.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 starsMedical Sector783rd out of 920 stocksPharmaceutical Preparations Industry368th out of 429 stocks 3.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on 9 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Travere Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.83% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Travere Therapeutics has recently increased by 8.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 2.8 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows3 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $364.00 in company stock.Percentage Held by InsidersOnly 3.75% of the stock of Travere Therapeutics is held by insiders.Read more about Travere Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($3.66) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -2.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 6.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Travere Therapeutics Stock (NASDAQ:TVTX)Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesMay 19 at 2:36 AM | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 16 at 1:14 PM | markets.businessinsider.comBuy Rating on Travere Therapeutics: Filspari’s Market Potential and Positive Financial OutlookMay 15, 2024 | globenewswire.comTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2024 | americanbankingnews.comWedbush Weighs in on Travere Therapeutics, Inc.'s FY2026 Earnings (NASDAQ:TVTX)May 12, 2024 | americanbankingnews.comFY2026 Earnings Estimate for Travere Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:TVTX)May 9, 2024 | globenewswire.comTravere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressMay 9, 2024 | americanbankingnews.comCanaccord Genuity Group Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $18.00May 9, 2024 | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Rating Reiterated by HC WainwrightMay 8, 2024 | finance.yahoo.comLoss-Making Travere Therapeutics, Inc. (NASDAQ:TVTX) Expected To Breakeven In The Medium-TermMay 8, 2024 | sfgate.comGossamer Bio: Q1 Earnings SnapshotMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Strong Filspari Sales and Favorable Regulatory ProspectsMay 7, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on Robust Drug Sales and Promising Market ExpansionMay 7, 2024 | markets.businessinsider.comBarclays Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)May 7, 2024 | msn.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comTravere Therapeutics Inc (TVTX) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth ...May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports Q1 2024 Results: A Mixed Financial Performance Amidst Strategic ...May 6, 2024 | msn.comTVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024May 6, 2024 | finance.yahoo.comTravere Therapeutics Reports First Quarter 2024 Financial ResultsMay 6, 2024 | globenewswire.comTravere Therapeutics Reports First Quarter 2024 Financial ResultsMay 5, 2024 | msn.comTravere Therapeutics Q1 2024 Earnings PreviewApril 29, 2024 | globenewswire.comTravere Therapeutics to Report First Quarter 2024 Financial ResultsApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US ProspectsApril 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue ProjectionsApril 24, 2024 | markets.businessinsider.comFILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere TherapeuticsSee More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/19/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$16.69 High Stock Price Target$30.00 Low Stock Price Target$9.00 Potential Upside/Downside+175.5%Consensus RatingModerate Buy Rating Score (0-4)2.64 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-87.94% Pretax Margin-226.71% Return on Equity-238.06% Return on Assets-52.87% Debt Debt-to-Equity Ratio5.10 Current Ratio2.78 Quick Ratio2.75 Sales & Book Value Annual Sales$145.24 million Price / Sales3.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book6.25Miscellaneous Outstanding Shares76,130,000Free Float73,274,000Market Cap$461.35 million OptionableOptionable Beta0.69 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Comp: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Comp: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Comp: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Comp: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Comp: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business OfficerMore ExecutivesKey CompetitorsLarimar TherapeuticsNASDAQ:LRMRAstria TherapeuticsNASDAQ:ATXSVerve TherapeuticsNASDAQ:VERVKalVista PharmaceuticalsNASDAQ:KALVOculisNASDAQ:OCSView All CompetitorsInsiders & InstitutionsJacobs Levy Equity Management Inc.Sold 593,513 shares on 5/16/2024Ownership: 1.477%California State Teachers Retirement SystemSold 3,930 shares on 5/16/2024Ownership: 0.098%Bayesian Capital Management LPBought 22,935 shares on 5/16/2024Ownership: 0.030%Affinity Asset Advisors LLCBought 125,000 shares on 5/15/2024Ownership: 0.164%Price T Rowe Associates Inc. MDBought 2,948 shares on 5/15/2024Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions TVTX Stock Analysis - Frequently Asked Questions Should I buy or sell Travere Therapeutics stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last twelve months. There are currently 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks. What is Travere Therapeutics' stock price target for 2024? 14 Wall Street research analysts have issued twelve-month price objectives for Travere Therapeutics' shares. Their TVTX share price targets range from $9.00 to $30.00. On average, they predict the company's share price to reach $16.69 in the next year. This suggests a possible upside of 175.5% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts. How have TVTX shares performed in 2024? Travere Therapeutics' stock was trading at $8.99 at the start of the year. Since then, TVTX shares have decreased by 32.6% and is now trading at $6.06. View the best growth stocks for 2024 here. When is Travere Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our TVTX earnings forecast. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its earnings results on Monday, May, 6th. The company reported ($1.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by $0.78. The firm had revenue of $41.40 million for the quarter, compared to analysts' expectations of $43.46 million. Travere Therapeutics had a negative net margin of 87.94% and a negative trailing twelve-month return on equity of 238.06%. The firm's quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.27) EPS. What ETF holds Travere Therapeutics' stock? Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.39% of its portfolio. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.23%), Jacobs Levy Equity Management Inc. (1.48%), Assenagon Asset Management S.A. (0.29%), Healthcare of Ontario Pension Plan Trust Fund (0.27%), Russell Investments Group Ltd. (0.24%) and Affinity Asset Advisors LLC (0.16%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVTX) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.